Amylyx Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Amylyx Pharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2021 to Q3 2024.
  • Amylyx Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $6.8M, a 33.1% decline year-over-year.
  • Amylyx Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $35.8M, a 6.27% increase year-over-year.
  • Amylyx Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $37.2M, a 71.1% increase from 2022.
  • Amylyx Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $21.7M, a 592% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $35.8M $6.8M -$3.37M -33.1% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $39.2M $9.57M -$380K -3.82% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $39.6M $9.92M +$2.42M +32.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $37.2M $9.53M +$3.44M +56.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-22
Q3 2023 $33.7M $10.2M +$4.65M +84.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $29.1M $9.95M +$4.24M +74.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $24.8M $7.5M +$3.11M +70.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $21.7M $6.09M +$5M +458% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-22
Q3 2022 $16.7M $5.52M +$4.72M +589% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $12M $5.71M +$5.05M +769% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $6.94M $4.39M +$3.81M +649% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $3.14M $1.09M Oct 1, 2021 Dec 31, 2021 10-K 2024-02-22
Q3 2021 $802K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $657K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $586K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.